Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $50 price target.
Stocks · News reference
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.
RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target
RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maintains $56 price target.
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.